P-glycoprotein (blood–brain barrier)

Ongoing clinical trials and approved products targeting P-glycoprotein (blood–brain barrier), in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

3ongoing imaging trials

0approved products

Target note

Full name: P-glycoprotein (ABCB1)
Nature: Efflux pump of the blood–brain barrier that pushes many drugs out of the brain.
Normal expression: Brain endothelium, bowel, liver, kidney.
Value: Measuring the function of the blood–brain barrier and its impairment.
Approaches: [11C]verapamil, [18F]MC225.
Indications explored: Alzheimer's disease, drug-resistant epilepsy, treatment-resistant depression, gliomas (research).
Points of caution: Research tool; quantification by kinetic modelling.

Ongoing imaging trials · 3Open in the radar →

Trial	Phase	Status	Sponsor	Countries
[18F]MC225 (P-glycoprotein)2023-508303-20-01 · Psychiatry and addiction	Phase 2	Recruiting	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	1
[18F]MC225 (P-glycoprotein)2024-518865-85-00 · Alzheimer's disease and cognitive disorders	Phase 2	Not yet recruiting	Universitair Medisch Centrum Groningen	1
[18F]MC225 (P-glycoprotein)2026-526106-32-00 · Brain (glioma, medulloblastoma…)	Phase 1	Not yet recruiting	Universitair Medisch Centrum Groningen	1

Cite this page

P-glycoprotein (blood–brain barrier). Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/p-glycoprotein-bloodbrain-barrier/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.